Navigation Links
Neurocrine Biosciences, Inc. Announces Proposed Public Offering of Common Stock
Date:1/18/2012

SAN DIEGO, Jan. 18, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it is offering to sell shares of its common stock in an underwritten public offering. Jefferies & Company, Inc. and Deutsche Bank Securities Inc. are acting as joint book-running managers for this offering, Piper Jaffray & Co. and Leerink Swann LLC are acting as co-managers for this offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

The securities described above are being offered by Neurocrine pursuant to a shelf registration statement previously filed with and declared effective by the Securities and Exchange Commission (the "SEC") on December 29, 2010. A preliminary prospectus supplement related to the offering has been filed with the SEC and is available on the SEC's Web site at http://www.sec.gov. Copies of the preliminary prospectus supplement relating to these securities may be obtained from Jefferies & Company, Inc., Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY, 10022, or by telephone at 877-547-6340, or by email at Prospectus_Department@Jefferies.com, or from Deutsche Bank Securities Inc., Attention: Prospectus Department, 100 Plaza One, Floor 2, Jersey City, NJ 07311-3901, or by telephone at 800-503-4611, or by email at Prospectus.cpdg@db.com. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Neurocrine Biosciences
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world, including endometriosis, stress-related disorders, pain, tardive dyskinesia, uterine fibroids, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders.

In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties such as those, among others, relating to Neurocrine's expectations regarding the completion, timing and size of its proposed public offeringAmong the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed offering, as well as risks and uncertainties associated with Neurocrine's business and finances in general, and the other risks described in Neurocrine's annual report on Form 10-K for the year ended December 31, 2010 and quarterly report on Form 10-Q for the quarter ended September 30, 2011. Neurocrine undertakes no obligation to update the statements contained in this press release after the date hereof.

 


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Neurocrine Mourns the Passing of Founder and Board Member Wylie Vale, Ph.D.
2. Neurocrine Biosciences to Present at the 30th Annual J.P. Morgan Healthcare Conference
3. Neurocrine Biosciences to Present at the 23rd Annual Piper Jaffray Health Care Conference
4. Neurocrine Biosciences to Present at the 2011 Credit Suisse Annual Health Care Conference
5. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2011 Financial Results
6. Neurocrine Biosciences Receives Second Milestone Payment of $20 Million Under Abbott Collaboration Agreement
7. Neurocrine Biosciences Announces Elagolix Scientific Presentations at the 67th Annual Meeting of the American Society for Reproductive Medicine
8. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
9. Neurocrine Biosciences Announces the Start of Phase II Study of Elagolix in Uterine Fibroids
10. Neurocrine Biosciences To Present at the Stifel Nicolaus 2011 Healthcare Conference
11. Neurocrine Biosciences Announces Conference Call and Webcast to Present Second Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... , Jan. 18, 2017  Dermata Therapeutics, LLC, ... to treat a variety of dermatological diseases, announces ... DMT210, in a Phase 2 acne rosacea study. ... downregulate the proinflammatory cytokines in the skin responsible ... rosacea. This clinical trial, DMT210-003, ...
(Date:1/18/2017)... Safe Rx LLC and Good Day Pharmacy, ... Loveland, Colorado , today announced the availability ... Day locations.     "Patients with prescriptions prone ... storage," said Milton Cohen , President & CEO ... a cup of coffee, you can protect your children ...
(Date:1/18/2017)... In China , we say Health is ... China,s Healthy Strategy originates. 2016 is ... and Social Development of the People,s Republic of ... council of the People,s Republic of China ... plan, identifying medical devices as one of the main breakthrough ...
Breaking Medicine Technology:
(Date:1/18/2017)... ... , ... At Hallmark Nameplate, their commitment to quality is what sets them ... 13485. This certification is another way they are making constant strides to provide all ... need. , The ISO 13485 Certification is a major accomplishment for Hallmark Nameplate and ...
(Date:1/18/2017)... ... January 18, 2017 , ... Michael J. Hennessy ... for its Center for Biosimilars, announced Michael J. Hennessy Associates, Inc. President Michael ... field of biosimilars through thought leader interaction in, live video and interactive digital ...
(Date:1/18/2017)... ... 18, 2017 , ... During pregnancy, women are at an ... those dental problems can increase the risk of pregnancy complications. Unfortunately, according to ... to get the dental care they need. Agoura Hills dentist, Philip Shindler ...
(Date:1/17/2017)... , ... January 17, 2017 , ... Anesthesia Progress ... for dentists to choose the best drug option for each patient. Dentists have several ... and better overall outcomes. , Researchers from the Tokyo Dental College in Tokyo, Japan ...
(Date:1/17/2017)... ... 17, 2017 , ... For breast cancer clinicians and researchers who were unable ... a more intimate review and analysis of its highlights, a novel half-day, complimentary meeting—the ... by Imedex on February 4, 2017 in Chicago. Chaired by Kathy S. Albain, MD, ...
Breaking Medicine News(10 mins):